Pasithea Therapeutics (KTTA) Retained Earnings (2020 - 2026)
Pasithea Therapeutics (KTTA) posted Retained Earnings of $127.6 million for Q1 2026, up 680082.25% sequentially from $18766.0 in Q4 2025, and up 340.38% YoY from $29.0 million in Q1 2025.
Pasithea Therapeutics (KTTA) Retained Earnings (2020 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Retained Earnings for 7 years, with the latest figure at $127.6 million in Q1 2026.
- Quarterly Retained Earnings rose 340.38% year-over-year to $127.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $127.6 million (up 340.38% YoY) and the FY2025 annual result came in at $18766.0, up 100.04% from the prior year.
- Retained Earnings grew to $127.6 million in Q1 2026 per KTTA's latest filing, from $18766.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $127.6 million in Q1 2026 and troughed at -$53.1 million in Q1 2025.
- A 5-year average of $17.5 million and a median of -$3144.0 in 2023 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 1878853.66% in 2024, down 1243633.81% in 2024.
- Over 5 years, Retained Earnings stood at -$661.0 in 2022, then plunged by 603.78% to -$4652.0 in 2023, then sank by 1065737.88% to -$49.6 million in 2024, then jumped by 100.04% to $18766.0 in 2025, then soared by 680082.25% to $127.6 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $127.6 million, $18766.0, and $72.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | 127.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 127.64 Mn |
| Dec 31, 2025 | 18,766.00 |
| Sep 30, 2025 | 72.09 Mn |
| Jun 30, 2025 | 72.03 Mn |
| Mar 31, 2025 | -53.10 Mn |
| Dec 31, 2024 | -49.58 Mn |
| Sep 30, 2024 | -35,317.00 |
| Jun 30, 2024 | -43.05 Mn |
| Mar 31, 2024 | 59.07 Mn |
| Dec 31, 2023 | -4,652.00 |
| Sep 30, 2023 | -7,717.00 |
| Jun 30, 2023 | -3,461.00 |
| Mar 31, 2023 | -3,144.00 |
| Dec 31, 2022 | -661.00 |
| Sep 30, 2022 | 57.95 Mn |
| Jun 30, 2022 | 57.97 Mn |
| Mar 31, 2022 | -3.79 Mn |
| Dec 31, 2021 | -2.21 Mn |
| Sep 30, 2021 | -2.84 Mn |
| Dec 31, 2020 | 267,401.00 |